Mesenchymal stromal cells in myeloid malignancies.
- Author:
Thomas SCHROEDER
1
;
Stefanie GEYH
;
Ulrich GERMING
;
Rainer HAAS
Author Information
- Publication Type:Review
- Keywords: Myelodysplastic syndromes; Acute myeloid leukemia; Mesenchymal stromal cells; Hematopoiesis; Niche
- MeSH: Animals; Hematopoiesis; Leukemia, Myeloid, Acute; Mesenchymal Stromal Cells*; Mice; Myelodysplastic Syndromes; Osteoblasts; Stem Cell Niche; Stem Cells
- From:Blood Research 2016;51(4):225-232
- CountryRepublic of Korea
- Language:English
- Abstract: Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are clonal myeloid disorders characterized by hematopoietic insufficiency. As MDS and AML are considered to originate from genetic and molecular defects of hematopoietic stem and progenitor cells (HSPC), the main focus of research in this field has focused on the characterization of these cells. Recently, the contribution of BM microenvironment to the pathogenesis of myeloid malignancies, in particular MDS and AML has gained more interest. This is based on a better understanding of its physiological role in the regulation of hematopoiesis. Additionally, it was demonstrated as a ‘proof of principle’ that genetic disruption of cells of the mesenchymal or osteoblastic lineage can induce MDS, MPS or AML in mice. In this review, we summarize the current knowledge about the contribution of the BM microenvironment, in particular mesenchymal stromal cells (MSC) to the pathogenesis of AML and MDS. Furthermore, potential models integrating the BM microenvironment into the pathophysiology of these myeloid disorders are discussed. Finally, strategies to therapeutically exploit this knowledge and to interfere with the crosstalk between clonal hematopoietic cells and altered stem cell niches are introduced.
